Web Desc
Integrated Pathways of Disease in NASH and NAFLD
Organizer(s): Scott L. Friedman, Arun J. Sanyal, Brent A. Tetri, Mary E. Rinella and Christopher R. Shepard
Date: January 20 - 24, 2019
Location: Eldorado Hotel & Spa, Santa Fe, NM, USA
Sponsored by Gilead Sciences, Inc., Novo Nordisk A/S and Pfizer Inc.
Summary of Meeting:
The global prevalence of nonalcoholic fatty liver disease (NAFLD) has risen precipitously over the past two decades in parallel with the worldwide obesity epidemic; however, there are no approved therapies. The more advanced form of the disease, non-alcoholic steatohepatitis (NASH), is associated with progressive fibrosis and an increased risk of liver cancer. Despite the growing number of systemic and liver-specific abnormalities identified in patients with NAFLD, a clear hierarchy of the relative importance of specific defects has not emerged. Furthermore, a clear understanding of which individuals are at highest risk for progression to advanced liver disease and cancer remains elusive. Thus, the field lacks an integrated understanding of risk prediction, pathogenesis and validated biomarkers to predict or track disease progression without reliance on liver biopsies. Therefore, the goals of this conference are to: 1) Explore genetic and ethnic contributions to NAFLD development; 2) Clarify underlying pathogenic defects in NAFLD and NASH, focusing on the specific contributions of lipotoxicity, the microbiome, innate immune signaling and drivers of fibrosis; and 3) Highlight emerging prognostic and diagnostic biomarkers that are yielding new, more streamlined clinical trial designs to evaluate novel therapies. As a result of this conference, attendees should gain a more holistic understanding of the unmet needs and new paths to advancing our understanding of NAFLD pathogenesis, diagnosis and therapy. The multidisciplinary nature of the topics and speakers promises to generate novel insights that represent convergent expertise and opinion. In doing so, new paradigms are likely to emerge that greatly inform the expanding number of emerging diagnostic markers and therapeutic agents. The conference comes at a propitious time when there is already sufficient basic translational and clinical research to extract important new insights, focus on unmet needs and refine research strategies for the future.
Scholarship Deadline: October 16 2018
Discounted Abstract Deadline: October 16 2018
Abstract Deadline: October 24 2018
Discounted Registration Deadline: November 27 2018
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
Gilead Sciences, Inc.Novo Nordisk A/SPfizer Inc.
We gratefully acknowledge additional support from these exhibitors at this conference:
AstraZeneca
We gratefully acknowledge additional support for this conference from:
GENFIT SAHanmi PharmaceuticalsInSphero Inc.Research Diets, Inc.
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Bristol-Myers Squibb Company

Novartis Institutes for BioMedical Research
We gratefully acknowledge the generous grant for this conference provided by:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Grant No. 1 R13 DK118909-01
Funding for this conference was made possible (in part) by 1 R13 DK118909-01 from NIDDK at the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, January 20 | 4:00PM - 8:00PM
Arrival and Registration
Room: Cava Santa Fe


Sunday, January 20 | 6:00PM - 8:00PM
Welcome Mixer
Room: Cava Santa Fe
No registration fees are used to fund alcohol served at this function.

Monday, January 21 | 7:00AM - 8:00AM
Breakfast
Room: Anasazi Ballroom


Monday, January 21 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Eldorado Grand Ballroom

Speaker 1 of 2
* Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA

Monday, January 21 | 8:00AM - 9:00AM
Welcome and Keynote Address
Room: Eldorado Grand Ballroom

Speaker 2 of 2
Gökhan S. Hotamisligil, Harvard School of Public Health, USA
Metainflammation and Fatty Liver Disease

Monday, January 21 | 9:00AM - 11:45AM
Genetic / Ethnic Determinants and Natural History of NAFLD
Room: Eldorado Grand Ballroom

Speaker 1 of 7
Stefano Romeo, University of Gothenburg, Sweden
Genetic Drivers of NAFLD

Monday, January 21 | 9:00AM - 11:45AM
Genetic / Ethnic Determinants and Natural History of NAFLD
Room: Eldorado Grand Ballroom


Coffee Break

Monday, January 21 | 9:00AM - 11:45AM
Genetic / Ethnic Determinants and Natural History of NAFLD
Room: Eldorado Grand Ballroom

Speaker 3 of 7
* Arun J. Sanyal, Virginia Commonwealth University Medical Center, USA
The Dynamic Nature of NAFLD: A Critical Analysis of Disease Progression and Regression

Monday, January 21 | 9:00AM - 11:45AM
Genetic / Ethnic Determinants and Natural History of NAFLD
Room: Eldorado Grand Ballroom

Speaker 4 of 7
Vincent WS Wong, Chinese University of Hong Kong, Hong Kong
NAFLD across the World – Similarities and Differences

Monday, January 21 | 9:00AM - 11:45AM
Genetic / Ethnic Determinants and Natural History of NAFLD
Room: Eldorado Grand Ballroom

Speaker 5 of 7
Yanling Ma, National Institutes of Health, USA
Short Talk: A Novel Retinol Dehydrogenase, HSD17B13 Contributes to the Pathogenesis of Non-Alcoholic Fatty Liver Disease

Monday, January 21 | 9:00AM - 11:45AM
Genetic / Ethnic Determinants and Natural History of NAFLD
Room: Eldorado Grand Ballroom

Speaker 6 of 7
Marlies Meisel, University of Pittsburgh, USA
Short Talk: Microbial Driven Inflammation is Associated with Hepatic Fibrosis in Tet2 Deficient Mice

Monday, January 21 | 9:00AM - 11:45AM
Genetic / Ethnic Determinants and Natural History of NAFLD
Room: Eldorado Grand Ballroom

Speaker 7 of 7
Shuang Wang, Icahn School of Medicine at Mount Sinai, USA
Short Talk: Epigenomic Drivers of Hepatic Stellate Cell Activation in Fibrosis and NASH

Monday, January 21 | 11:45AM - 5:00PM
On Own for Lunch


Monday, January 21 | 11:45AM - 1:00PM
Poster Setup
Room: Anasazi Ballroom


Monday, January 21 | 1:00PM - 10:00PM
Poster Viewing
Room: Anasazi Ballroom


Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Biomarkers
Room: Eldorado Grand Ballroom

Speaker 1 of 6
* Yaron Rotman, NIDDK, National Institutes of Health, USA

Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Biomarkers
Room: Eldorado Grand Ballroom

Speaker 2 of 6
Andrea Dennis, Perspectum Diagnostics, USA
Multi-Parametric MRI as A Composite Biomarker for NASH and NASH with Fibrosis

Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Biomarkers
Room: Eldorado Grand Ballroom

Speaker 3 of 6
Shyam Sundhar Bale, Draper, USA
High-Throughput Microfluidic Microphysiological System to Recapitulate Hepatic Microenvironment

Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Biomarkers
Room: Eldorado Grand Ballroom

Speaker 4 of 6
Loning Fu, Baylor College of Medicine, USA
Circadian Dysfunction Is an Independent Risk Factor for NAFLD and NASH

Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Biomarkers
Room: Eldorado Grand Ballroom

Speaker 5 of 6
Eloy D. Hernandez, Genomics Institute of the Novartis Research Foundation, USA
Tropifexor-Mediated Abrogation of Steatohepatitis and Fibrosis is Associated with Anti-Oxidative Gene Expression Profile in Rodents

Monday, January 21 | 2:30PM - 4:30PM
Workshop 1: Biomarkers
Room: Eldorado Grand Ballroom

Speaker 6 of 6
Raquel Saborano, University of Birmingham, UK
How Can Stable Isotopic Tracer Studies Elucidate Metabolism in Liver Disease?

Monday, January 21 | 4:30PM - 5:00PM
Coffee Available
Room: Concourse


Monday, January 21 | 5:00PM - 7:15PM
Metabolic Drivers of Cell Stress and Injury
Room: Eldorado Grand Ballroom

Speaker 1 of 7
* Anna Mae Diehl, Duke University, USA

Monday, January 21 | 5:00PM - 7:15PM
Metabolic Drivers of Cell Stress and Injury
Room: Eldorado Grand Ballroom

Speaker 2 of 7
Harmeet Malhi, Mayo Clinic, USA
Lipotoxic Stress and the Pathogenesis of NASH

Monday, January 21 | 5:00PM - 7:15PM
Metabolic Drivers of Cell Stress and Injury
Room: Eldorado Grand Ballroom

Speaker 3 of 7
Michael Trauner, Medical University of Vienna, Austria
Bile Acid Regulation of Metabolism in the Development and Progression of NAFLD

Monday, January 21 | 5:00PM - 7:15PM
Metabolic Drivers of Cell Stress and Injury
Room: Eldorado Grand Ballroom

Speaker 4 of 7
Johan Auwerx, École Polytechnique Fédérale de Lausanne, Switzerland
A Novel Approach for NAD Boosting

Monday, January 21 | 5:00PM - 7:15PM
Metabolic Drivers of Cell Stress and Injury
Room: Eldorado Grand Ballroom

Speaker 5 of 7
Neha Bhat, Yale University, USA
Short Talk: Dyrk1b: A Novel Driver of Hepatic Lipid Metabolism

Monday, January 21 | 5:00PM - 7:15PM
Metabolic Drivers of Cell Stress and Injury
Room: Eldorado Grand Ballroom

Speaker 6 of 7
Mariana Acuna-Aravena, Weill Cornell Medical College, USA
Short Talk: Protective Role for Acot12 in the Pathogenesis of Hepatic Insulin Resistance and Nonalcoholic Fatty Liver Disease (NAFLD)

Monday, January 21 | 5:00PM - 7:15PM
Metabolic Drivers of Cell Stress and Injury
Room: Eldorado Grand Ballroom

Speaker 7 of 7
Victoria Slaughter, University of Central Florida, USA
Short Talk: Development and Characterization of A Two-Organ Human-on-a-Chip NAFLD Model

Monday, January 21 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Anasazi Ballroom
No registration fees are used to fund alcohol served at this function.

Monday, January 21 | 7:30PM - 10:00PM
Poster Session 1
Room: Anasazi Ballroom


Tuesday, January 22 | 7:00AM - 8:00AM
Breakfast
Room: Anasazi Ballroom


Tuesday, January 22 | 8:00AM - 11:00AM
Drivers and Consequences of Hepatic Lipotoxicity in NAFLD
Room: Eldorado Grand Ballroom

Speaker 1 of 8
* Karen D. Corbin, AdventHealth, USA

Tuesday, January 22 | 8:00AM - 11:00AM
Drivers and Consequences of Hepatic Lipotoxicity in NAFLD
Room: Eldorado Grand Ballroom

Speaker 2 of 8
Brent A. Tetri, St. Louis University, USA
Fatty Acid Dysregulation in NAFLD

Tuesday, January 22 | 8:00AM - 11:00AM
Drivers and Consequences of Hepatic Lipotoxicity in NAFLD
Room: Eldorado Grand Ballroom

Speaker 3 of 8
Petra Hirsova, Mayo Clinic, USA
Sublethal Hepatocyte Injury as a Driver of Liver Inflammation in NASH

Tuesday, January 22 | 8:00AM - 11:00AM
Drivers and Consequences of Hepatic Lipotoxicity in NAFLD
Room: Eldorado Grand Ballroom


Coffee Break

Tuesday, January 22 | 8:00AM - 11:00AM
Drivers and Consequences of Hepatic Lipotoxicity in NAFLD
Room: Eldorado Grand Ballroom

Speaker 5 of 8
Sheila Collins, Vanderbilt University Medical Center, USA
Metabolic Benefits from Activating Thermogenesis and Energy Expenditure

Tuesday, January 22 | 8:00AM - 11:00AM
Drivers and Consequences of Hepatic Lipotoxicity in NAFLD
Room: Eldorado Grand Ballroom

Speaker 6 of 8
James P. Hardwick, Northeast Ohio Medical University, USA
Cytochrome P450-mediated Lipotoxicity

Tuesday, January 22 | 8:00AM - 11:00AM
Drivers and Consequences of Hepatic Lipotoxicity in NAFLD
Room: Eldorado Grand Ballroom

Speaker 7 of 8
Paula J. Rote, Northeast Ohio Medical University, USA
Short Talk: Cytochrome P450 Fatty Acid Omega-Hydroxylase, Avenues for Fatty Acid Oxidation or Fatty Acid Synthesis in NAFLD Progression

Tuesday, January 22 | 8:00AM - 11:00AM
Drivers and Consequences of Hepatic Lipotoxicity in NAFLD
Room: Eldorado Grand Ballroom

Speaker 8 of 8
Aline Mello, University of California, Davis, USA
Short Talk: Soluble Epoxide Hydrolase is a Potential Therapeutic Target for Non-Alcoholic Steatohepatitis

Tuesday, January 22 | 11:00AM - 5:00PM
On Own for Lunch


Tuesday, January 22 | 11:00AM - 1:00PM
Poster Setup
Room: Anasazi Ballroom


Tuesday, January 22 | 1:00PM - 10:00PM
Poster Viewing
Room: Anasazi Ballroom


Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Therapeutics
Room: Eldorado Grand Ballroom

Speaker 1 of 7
* Maria Elena Fuentes, Blade Therapeutics, USA

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Therapeutics
Room: Eldorado Grand Ballroom

Speaker 2 of 7
Anissa A. Widjaja, DUKE-NUS Medical School, Singapore
IL-11 is A Novel Therapeutic Target in Non-Alcoholic Steatohepatitis

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Therapeutics
Room: Eldorado Grand Ballroom

Speaker 3 of 7
Cecile Vernochet, Bill & Melinda Gates Medical Research Institute, USA
Validation of a Novel Human Adipocyte Anti-Lipolysis CRISPR-Based Screen

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Therapeutics
Room: Eldorado Grand Ballroom

Speaker 4 of 7
Wen-Wei Tsai, Gilead Sciences, USA
Antisense-Mediated Reduction of Hepatic Autotaxin as a Potential Therapeutic Strategy for Non-Alcoholic Steatohepatitis

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Therapeutics
Room: Eldorado Grand Ballroom

Speaker 5 of 7
Maureen O'Connor, Forbius, USA
Development of AVID200, a TGF-ß inhibitor with Optimal Isoform-Selectivity For Treatment of Fibrotic Diseases

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Therapeutics
Room: Eldorado Grand Ballroom

Speaker 6 of 7
Emily P. Offer, Redx Pharma, UK
ROCK2 Inhibitors for the Treatment of Fibrosis

Tuesday, January 22 | 2:30PM - 4:30PM
Workshop 2: Therapeutics
Room: Eldorado Grand Ballroom

Speaker 7 of 7
Kyle S. McCommis, Washington University School of Medicine, USA
Mitochondrial Pyruvate Carrier Modulators to Treat Nonalcoholic Steatohepatitis

Tuesday, January 22 | 4:30PM - 5:00PM
Coffee Available
Room: Concourse


Tuesday, January 22 | 5:00PM - 7:00PM
Innate Immune and Inflammatory Signaling
Room: Eldorado Grand Ballroom

Speaker 1 of 6
* Anutosh Chakraborty, St. Louis University, USA

Tuesday, January 22 | 5:00PM - 7:00PM
Innate Immune and Inflammatory Signaling
Room: Eldorado Grand Ballroom

Speaker 2 of 6
Gyongyi Szabo, University of Massachusetts Medical School, USA
Innate Immune Cell Activation in NASH: Mechanisms and Therapeutic Targets

Tuesday, January 22 | 5:00PM - 7:00PM
Innate Immune and Inflammatory Signaling
Room: Eldorado Grand Ballroom

Speaker 3 of 6
Wajahat Z. Mehal, Yale University, USA
Innate Immune Signaling and NASH

Tuesday, January 22 | 5:00PM - 7:00PM
Innate Immune and Inflammatory Signaling
Room: Eldorado Grand Ballroom

Speaker 4 of 6
Annie J. Kruger, MedStar Georgetown University Hospital, USA
Short Talk: Chemokine Receptor 2 and 5 Antagonism Attenuates Mouse Primary Hepatic Stellate Cell Activity and Prevents Skewing of Human Macrophages in a Co-Culture System

Tuesday, January 22 | 5:00PM - 7:00PM
Innate Immune and Inflammatory Signaling
Room: Eldorado Grand Ballroom

Speaker 5 of 6
Svetlana Marukian, Axcella Health, USA
Short Talk: Unique Composition of Endogenous Modulators Impact Metabolic, Inflammation, and Fibrotic Markers in NAFLD/NASH Model Systems

Tuesday, January 22 | 5:00PM - 7:00PM
Innate Immune and Inflammatory Signaling
Room: Eldorado Grand Ballroom

Speaker 6 of 6
Bishuang Cai, Columbia University, USA
Short Talk: The Role of MerTK and MerTK Cleavage in NASH-Related Liver Fibrosis

Tuesday, January 22 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Anasazi Ballroom
No registration fees are used to fund alcohol served at this function.

Tuesday, January 22 | 7:30PM - 10:00PM
Poster Session 2
Room: Anasazi Ballroom


Wednesday, January 23 | 7:00AM - 8:00AM
Breakfast
Room: Anasazi Ballroom


Wednesday, January 23 | 8:00AM - 11:15AM
Integrative and Systemic Biology of NAFLD
Room: Eldorado Grand Ballroom

Speaker 1 of 9
* Brian N. Finck, Washington University School of Medicine, USA

Wednesday, January 23 | 8:00AM - 11:15AM
Integrative and Systemic Biology of NAFLD
Room: Eldorado Grand Ballroom

Speaker 2 of 9
Thomas P. Burris, Washington University School of Medicine, USA
Targeting Orphan Nuclear Receptors for Treatment of NASH

Wednesday, January 23 | 8:00AM - 11:15AM
Integrative and Systemic Biology of NAFLD
Room: Eldorado Grand Ballroom

Speaker 3 of 9
Noura S. Abul-Husn, Icahn School of Medicine at Mount Sinai, USA
Leveraging Genomics and Biobanks to Accelerate Drug Discovery in NASH

Wednesday, January 23 | 8:00AM - 11:15AM
Integrative and Systemic Biology of NAFLD
Room: Eldorado Grand Ballroom


Coffee Break

Wednesday, January 23 | 8:00AM - 11:15AM
Integrative and Systemic Biology of NAFLD
Room: Eldorado Grand Ballroom

Speaker 5 of 9
Ira Tabas, Columbia University, USA
The Role of Hepatocyte TAZ in NASH and NASH-HCC

Wednesday, January 23 | 8:00AM - 11:15AM
Integrative and Systemic Biology of NAFLD
Room: Eldorado Grand Ballroom

Speaker 6 of 9
Ariel E. Feldstein, University of California, San Diego, USA
Extracellular Vesicles in NASH: From Contributors to Disease Pathogenesis to Novel Biomarkers

Wednesday, January 23 | 8:00AM - 11:15AM
Integrative and Systemic Biology of NAFLD
Room: Eldorado Grand Ballroom

Speaker 7 of 9
Kavita Jadhav, Columbia University, USA
Short Talk: Identifying The Role of Tribbles1 in Hepatic Lipogenesis

Wednesday, January 23 | 8:00AM - 11:15AM
Integrative and Systemic Biology of NAFLD
Room: Eldorado Grand Ballroom

Speaker 8 of 9
Srivatsan Kidambi, University of Nebraska, USA
Short Talk: Stiffness Induces NAFLD-like Metabolic Dysfunction in Primary Hepatocytes

Wednesday, January 23 | 8:00AM - 11:15AM
Integrative and Systemic Biology of NAFLD
Room: Eldorado Grand Ballroom

Speaker 9 of 9
Sebastian Prill, IMED Biotech Unit, AstraZeneca, Sweden
Short Talk: Inducing Liver Fat Accumulation in 3D Spheroids of Primary Human Hepatocytes: Towards a Human in vitro Model of NAFLD

Wednesday, January 23 | 11:15AM - 5:00PM
On Own for Lunch


Wednesday, January 23 | 11:15AM - 1:00PM
Poster Setup
Room: Anasazi Ballroom


Wednesday, January 23 | 1:00PM - 10:00PM
Poster Viewing
Room: Anasazi Ballroom


Wednesday, January 23 | 4:30PM - 5:00PM
Coffee Available
Room: Concourse


Wednesday, January 23 | 5:00PM - 7:15PM
Fibrosis and Cancer - Mechanisms and Markers
Room: Eldorado Grand Ballroom

Speaker 1 of 7
* Harmeet Malhi, Mayo Clinic, USA

Wednesday, January 23 | 5:00PM - 7:15PM
Fibrosis and Cancer - Mechanisms and Markers
Room: Eldorado Grand Ballroom

Speaker 2 of 7
Scott L. Friedman, Icahn School of Medicine at Mount Sinai, USA
Hepatic Stellate Cells in Non-Alcoholic Steatohepatitis

Wednesday, January 23 | 5:00PM - 7:15PM
Fibrosis and Cancer - Mechanisms and Markers
Room: Eldorado Grand Ballroom

Speaker 3 of 7
Jelena Mann, Newcastle University, UK
Epigenetics of Fibrosis and Cancer in Liver Disease

Wednesday, January 23 | 5:00PM - 7:15PM
Fibrosis and Cancer - Mechanisms and Markers
Room: Eldorado Grand Ballroom

Speaker 4 of 7
Chinweike Ukomadu, Novartis Institutes for Biomedical Research, USA
BMP9 is a Pro-Fibrotic, Anti-Regenerative Factor in the Liver

Wednesday, January 23 | 5:00PM - 7:15PM
Fibrosis and Cancer - Mechanisms and Markers
Room: Eldorado Grand Ballroom

Speaker 5 of 7
Hongji Zhang, Ohio State University, USA
Short Talk: The Role of Neutrophil Extracellular Traps in Nonalcoholic Steatohepatitis-Associated Hepatocellular Carcinoma

Wednesday, January 23 | 5:00PM - 7:15PM
Fibrosis and Cancer - Mechanisms and Markers
Room: Eldorado Grand Ballroom

Speaker 6 of 7
Annelie Falkevall, Karolinska Institutet, Sweden
Short Talk: Reducing VEGF-B Signaling Ameliorates Hepatic Steatosis and Prevents Development of Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis and Hepatocellular Carcinoma

Wednesday, January 23 | 5:00PM - 7:15PM
Fibrosis and Cancer - Mechanisms and Markers
Room: Eldorado Grand Ballroom

Speaker 7 of 7
Brian Schwartz, Camp4 Therapeutics, USA
Gene Circuitry Mapping Identifies Novel Approaches for Reducing PNPLA3 148M Expression as a Treatment for
NAFLD/NASH


Wednesday, January 23 | 7:15PM - 8:15PM
Social Hour with Lite Bites
Room: Anasazi Ballroom
No registration fees are used to fund alcohol served at this function.

Wednesday, January 23 | 7:30PM - 10:00PM
Poster Session 3
Room: Anasazi Ballroom


Thursday, January 24 | 7:00AM - 8:00AM
Breakfast
Room: Anasazi Ballroom


Thursday, January 24 | 8:00AM - 11:15AM
Modalities of NAFLD Diagnosis and Prognosis Assessment
Room: Eldorado Grand Ballroom

Speaker 1 of 9
* Mary E. Rinella, Northwestern University, USA

Thursday, January 24 | 8:00AM - 11:15AM
Modalities of NAFLD Diagnosis and Prognosis Assessment
Room: Eldorado Grand Ballroom

Speaker 2 of 9
Shusuke Toden, Molecular Stethoscope, USA
Whole-Transcriptome Circulating Cell-Free mRNA Analysis to Diagnose and Stratify NAFLD

Thursday, January 24 | 8:00AM - 11:15AM
Modalities of NAFLD Diagnosis and Prognosis Assessment
Room: Eldorado Grand Ballroom

Speaker 3 of 9
Rohit Loomba, University of California, San Diego, Salk Institute, USA
Serum and Imaging Biomarkers

Thursday, January 24 | 8:00AM - 11:15AM
Modalities of NAFLD Diagnosis and Prognosis Assessment
Room: Eldorado Grand Ballroom


Coffee Break

Thursday, January 24 | 8:00AM - 11:15AM
Modalities of NAFLD Diagnosis and Prognosis Assessment
Room: Eldorado Grand Ballroom

Speaker 5 of 9
Gabe A. Kwong, Glympse Bio, USA
Assessing Matrix Turnover and Proteolysis

Thursday, January 24 | 8:00AM - 11:15AM
Modalities of NAFLD Diagnosis and Prognosis Assessment
Room: Eldorado Grand Ballroom

Speaker 6 of 9
Yi Luo, Bristol-Myers Squibb, USA
Identification of Serum Biomarkers of Advanced Fibrosis in NASH Patients

Thursday, January 24 | 8:00AM - 11:15AM
Modalities of NAFLD Diagnosis and Prognosis Assessment
Room: Eldorado Grand Ballroom

Speaker 7 of 9
Lars Verschuren, TNO, Netherlands
Short Talk: Identification and Verification of Human Biomarkers for Early Detection of NASH-Induced Fibrosis

Thursday, January 24 | 8:00AM - 11:15AM
Modalities of NAFLD Diagnosis and Prognosis Assessment
Room: Eldorado Grand Ballroom

Speaker 8 of 9
Madhulika Tripathi, Duke-NUS Medical School Singapore, Singapore
Short Talk: Role of YAP (Yes-Associated Protein) in Regulating FGF21 Expression during NAFLD Progression

Thursday, January 24 | 8:00AM - 11:15AM
Modalities of NAFLD Diagnosis and Prognosis Assessment
Room: Eldorado Grand Ballroom

Speaker 9 of 9
Yaron Rotman, NIDDK, National Institutes of Health, USA
Short Talk: Human and Murine Studies Identify RORA as a Modulator of Steatosis and Severity of Non-Alcoholic Fatty Liver Disease

Thursday, January 24 | 11:15AM - 5:00PM
On Own for Lunch


Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Animal Models
Room: Eldorado Grand Ballroom

Speaker 1 of 6
* Henrik H. Hansen, Gubra, Denmark
A Novel Gubra Amylin NASH (GAN) Diet-Induced ob/ob Mouse Model Of Biopsy-Confirmed Non-Alcoholic Steatohepatitis

Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Animal Models
Room: Eldorado Grand Ballroom

Speaker 2 of 6
Roeland Hanemaaijer, TNO Metabolic Health Research, Netherlands
Development of a Diet-Induced Disease-Mimicking in vitro Model of Non-Alcoholic Steatohepatitis (NASH)/Fibrosis

Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Animal Models
Room: Eldorado Grand Ballroom

Speaker 3 of 6
Julia S.K Nilsson, Lund University, Sweden
The NIF Mouse - A New and Unique Model of NASH

Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Animal Models
Room: Eldorado Grand Ballroom

Speaker 4 of 6
Alexander W. Coutts, Recombinetics, Inc., USA
A PNPLA3I148M Gene-Edited Ossabaw Swine Model of Nonalcoholic Steatohepatitis (NASH)

Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Animal Models
Room: Eldorado Grand Ballroom

Speaker 5 of 6
Henry N. Ginsberg, Columbia University College of Physicians and Surgeons, USA
Hepatocyte-Specific Depletion of Nuclear Membrane Proteins LAP1 or torsinA Causes Nonalcoholic Steatohepatitis with Decreased VLDL Secretion and Abnormal Lipid Droplet Accumulation in Chow Fed Mice

Thursday, January 24 | 2:30PM - 4:30PM
Workshop 3: Animal Models
Room: Eldorado Grand Ballroom

Speaker 6 of 6
Raul C. Camacho, Janssen, USA
Non-Alcoholic Steatohepatitis (NASH) Is Inducible by Adding Fructose to a High Fat/Cholesterol Diet in Cynomolgus Monkeys

Thursday, January 24 | 4:30PM - 5:00PM
Coffee Available
Room: Concourse


Thursday, January 24 | 5:00PM - 6:45PM
Clinical Trial Design and Emerging Therapies
Room: Eldorado Grand Ballroom

Speaker 1 of 4
* Brent A. Tetri, St. Louis University, USA

Thursday, January 24 | 5:00PM - 6:45PM
Clinical Trial Design and Emerging Therapies
Room: Eldorado Grand Ballroom

Speaker 2 of 4
Mary E. Rinella, Northwestern University, USA
Clinical Trial Design, Endpoints and Regulatory Science in NAFLD Accelerating Patient Accrual and Shortening Trial Length

Thursday, January 24 | 5:00PM - 6:45PM
Clinical Trial Design and Emerging Therapies
Room: Eldorado Grand Ballroom

Speaker 3 of 4
Manal F. Abdelmalek, Duke University Medical Center, USA
Emerging Therapies for the Treatment of NASH

Thursday, January 24 | 5:00PM - 6:45PM
Clinical Trial Design and Emerging Therapies
Room: Eldorado Grand Ballroom

Speaker 4 of 4
Daniel Edward Lefever, University of Pittsburgh, USA
Short Talk: A Quantitative Systems Pharmacology (QSP) Approach to Repurposing Drugs for Non-Alcoholic Fatty Liver Disease (NAFLD)

Thursday, January 24 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions
Room: Eldorado Grand Ballroom

Speaker 1 of 1
* Arun J. Sanyal, Virginia Commonwealth University Medical Center, USA

Thursday, January 24 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Anasazi Ballroom
No registration fees are used to fund alcohol served at this function.

Thursday, January 24 | 8:00PM - 11:00PM
Entertainment
Room: Anasazi Ballroom
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, January 24 | 8:00PM - 11:00PM
Cash Bar
Room: Anasazi Ballroom


Friday, January 25 | 10:24AM - 10:24AM
Departure


*Session Chair.